Jonathan B Perlin
CIK 1373493 · Pres-Clinical Operations & CMO · last filed 2021-08-04
Jonathan B Perlin is a Pres-Clinical Operations & CMO who has filed 56 SEC Form 4 insider transactions across 1 company since 2011. The most recent filing, for HCA, was dated Aug 4, 2021. Across all open-market trades the lifetime net is −$83.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $19.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HCA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE PARK PLAZA
NASHVILLE, TN 37203
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HCA | Pres-Clinical Operations & CMO | 41,842 | $467.31 | $19.55M | -$83.10M | 52 | 2021-08-04 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-04 | HCA | Mixed | −40,000 | -$10.00M | EDGAR |
| 2021-04-27 | HCA | Mixed | −62,305 | -$25.19M | EDGAR |
| 2021-02-22 | HCA | Mixed | +8,603 | -$974.8K | EDGAR |
| 2021-02-05 | HCA | Mixed | +31,654 | -$3.44M | EDGAR |
| 2020-11-17 | HCA | Mixed | +3,491 | -$4.56M | EDGAR |
| 2020-11-12 | HCA | Mixed | +17,002 | -$1.63M | EDGAR |
| 2020-11-09 | HCA | Mixed | — | -$1.31M | EDGAR |
| 2020-02-21 | HCA | Mixed | +7,591 | -$496.8K | EDGAR |
| 2020-01-31 | HCA | Grant (A) | — | $0 | EDGAR |
| 2019-02-27 | HCA | Mixed | +1,198 | -$101.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.